A study suggests that a reduced dose of enfortumab vedotin may lower toxicity in older patients with urothelial carcinoma, ...

Learn how intelligent medical records enhance patient care, streamline workflows, and improve healthcare outcomes through ...

Explore the FDA fast track oncology drugs granted in September 2026, advancing treatments for various cancer types.

On Oct. 2, the U.S. Food and Drug Administration (FDA) approved pirtobrutinib (Jaypirca) for adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who ...

Recent headlines on leadership appointments, executive transitions and notable recognitions spotlight the leaders helping to ...

At WCLC 2026, three thoracic oncologists discuss first-line regimen selection, subcutaneous dosing, dermatologic prophylaxis, and dose modifications in EGFR-mutant NSCLC. Subcutaneous amivantamab has ...

Tarlatamab (Idella) provided meaningful intracranial activity without added safety concerns in a real-world analysis of patients with small cell lung cancer (SCLC) and brain metastases, including ...

Community oncology practices can point to advantages such as care closer to home, greater affordability, and a more ...

Bundled payment models can offer employers more predictable cancer costs, but implementing them in community oncology can be complicated by financial risk and administrative demands. At the 2026 ...